1 / 38

Where Do We Go From Here? Ongoing Clinical Trials and Future Directions

Where Do We Go From Here? Ongoing Clinical Trials and Future Directions. Agenda. Locally Advanced Pancreas Cancer Role of (Chemo)Radiotherapy?. Pancreas Cancer – Disease Distribution Patterns. FFCD-SFRO Phase III 5FU-Cis-RT + Gem vs Gemcitabine. ECOG 4201 (N= 71). Optimal Therapy LAPC?.

unity
Download Presentation

Where Do We Go From Here? Ongoing Clinical Trials and Future Directions

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Where Do We Go From Here?Ongoing Clinical Trials and Future Directions

  2. Agenda

  3. Locally Advanced Pancreas CancerRole of (Chemo)Radiotherapy?

  4. Pancreas Cancer – Disease Distribution Patterns

  5. FFCD-SFRO Phase III 5FU-Cis-RT + Gem vs Gemcitabine

  6. ECOG 4201 (N= 71)

  7. Optimal Therapy LAPC?

  8. Pancreas Cancer & Thromboses

  9. CONKO-004 (LBA #4506)Randomized Phase II

  10. CONKO-004 Results

  11. FRAGEM Trial (Abst #O-6503)Randomized Phase IIb

  12. FRAGEM Results

  13. Conclusions: CONKO-004, FRAGEM Trials

  14. Drug Development

  15. Molecular Pathogenesis of PC

  16. Novel Cytotoxics

  17. New Cytotoxics / Combinations

  18. Rand. Phase II Gem + Endotag-1

  19. CO-101 (CP-4126)

  20. New Targets, New Drugs

  21. Enhancing Apoptosis

  22. DR-5, Antagonists & Stem Cells

  23. Phase Ib Gemcitabine + AMG 655

  24. SWOG S0727Phase I → Randomized Phase II

  25. PARP Inhibitors

  26. Poly (ADP-Ribose) Polymerase (PARP)

  27. Loss of Functional BRCA1 or 2 Affects DNA Double-Strand Break Repair Pathway

  28. Why PARP Inhibitors in Panc Ca?

  29. PARP Inhibitor Trials in PC

  30. Correlative Questions

  31. Selected Targeted Approaches in PC

  32. Phase III TrialsLocally Advanced, Metastatic PC

  33. Randomized Phase II TrialsLocally Advanced, Metastatic PC

  34. (Many) Challenges Include..

More Related